Bristol Myers Squibb's Corporate Customers have recorded an advance in their cost of revenue by 8.42 % in the 1 quarter 2026 year on year, sequentially costs of revenue were trimmed by -5.98 %. During the corresponding time, Bristol Myers Squibb Company recorded a revenue increase by 2.57 % year on year, sequentially revenue fell by -8.1 %. While revenue at the Bristol Myers Squibb Company's corporate clients recorded rose by 5.5 % year on year, sequentially revenue fell by -2.35 %.
Bristol Myers Squibb's Customers have recorded an advance in their cost of revenue by 8.42 % in the 1 quarter 2026 year on year, sequentially costs of revenue were trimmed by -5.98 %, for the same period Bristol Myers Squibb Company recorded revenue increase by 2.57 % year on year, sequentially revenue fell by -8.1 %.
Bristol Myers Squibb's Comment on Sales, Marketing and Customers
The company markets its products directly to healthcare professionals and organizations, including doctors, nurse practitioners, physician assistants, pharmacists, technologists, hospitals, pharmacy benefit managers (PBMs), and managed care organizations (MCOs). It also provides information to U.S. consumers through various advertising channels. The company educates medical professionals on product risks and benefits and seeks to secure product access on formularies and reimbursement plans such as Medicare Part D. Marketing and sales efforts are conducted by specialized organizations and sales forces targeting physician specialists and managed care entities. Products are primarily sold to wholesalers, distributors, specialty pharmacies, and, to a lesser extent, retailers, hospitals, clinics, and government agencies. In the U.S., direct-to-patient offerings have been announced for several products. Specific products, including Revlimid and Pomalyst, are distributed through contracted pharmacies under mandatory risk-management programs (REMS). Camzyos is also available only through the Camzyos REMS Program. Internationally, Revlimid and Imnovid are distributed under similar risk-management programs adapted to local regulations. Distribution channels vary by country and program design and may include hospitals or retail pharmacies.
Encouraging Advances and Financial Intricacies of Bristol Myers Squibb and BioNTech s PD-L1xVEGF-A Bispecific Antibody in Small Cell Lung Cancer: A Multifaceted Analysis In a significant stride towards enhancing therapeutic interventions for Small Cell Lung Cancer (SCLC), BioNTech SE and Bristol Myers Squibb (BMS) have unveiled compelling interim data from a global randomized Phase 2 trial involving their investigational bispecific antibody, pumitamig (BNT327/BMS986545). This innovative antibody targets PD-L1 and VEGF-A, and when combined with chemotherapy, has shown promising antitumor activity in patients with extensive-stage SCLC (ES-SCLC).The Phase 2 trial results, disclosed during the prestigious IASLC ...
In a groundbreaking move that promises to reshape the landscape of drug development, AI Proteins, Inc. a pioneer in computational de novo protein design has announced a strategic Research Collaboration and Option Agreement with the pharmaceutical giant Bristol Myers Squibb (BMS). This partnership aims to harness the power of AI-driven miniprotein therapeutics, potentially yielding innovations that could have a substantial impact on a variety of diseases.Headquartered in Boston, AI Proteins specializes in creating therapeutic miniproteins through a sophisticated AI discovery platform. This collaboration marks a pivotal moment, allowing both companies to synergistically combine their strengths to develop novel...
SystImmune and Bristol Myers Squibb Form Global Partnership for Innovative Cancer Treatment In a groundbreaking collaboration, clinical-stage biopharmaceutical company SystImmune and Bristol Myers Squibb (BMY) have joined forces to develop and commercialize BL-B01D1, a potentially revolutionary EGFRxHER3 bispecific antibody-drug conjugate (ADC). This strategic partnership will see both companies working together to bring this cutting-edge therapy to patients in the United States. Under the terms of the agreement, SystImmune will retain sole responsibility for the manufacturing and supply of BL-B01D1. This collaboration highlights the companies shared commitment to providing innovative treatment opt...
Bristol Myers Squibb’s Comment on Sales, Marketing and Customers
The company markets its products directly to healthcare professionals and organizations, including doctors, nurse practitioners, physician assistants, pharmacists, technologists, hospitals, pharmacy benefit managers (PBMs), and managed care organizations (MCOs). It also provides information to U.S. consumers through various advertising channels. The company educates medical professionals on product risks and benefits and seeks to secure product access on formularies and reimbursement plans such as Medicare Part D. Marketing and sales efforts are conducted by specialized organizations and sales forces targeting physician specialists and managed care entities. Products are primarily sold to wholesalers, distributors, specialty pharmacies, and, to a lesser extent, retailers, hospitals, clinics, and government agencies. In the U.S., direct-to-patient offerings have been announced for several products. Specific products, including Revlimid and Pomalyst, are distributed through contracted pharmacies under mandatory risk-management programs (REMS). Camzyos is also available only through the Camzyos REMS Program. Internationally, Revlimid and Imnovid are distributed under similar risk-management programs adapted to local regulations. Distribution channels vary by country and program design and may include hospitals or retail pharmacies.
Sources:
Bristol myers Squibb Company’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Bristol myers Squibb Company’s corporate clients.
For your research, we’ve provided 9 tables on Bristol myers Squibb Company corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
97.21 %
5.52 % 